RxDoctor Payments Data

Amy Goff-Yates

Nurse Practitioner · Germantown, OHNPI 1306407101

Payments from drug & device makers

$4,676in general payments, 2019–2025

Across 290 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$867
  • Novartis$490
  • Biohaven Pharmaceuticals, Inc.$338
  • Lilly USA, LLC$306
  • Biohaven Pharmaceutical Holding Company Ltd.$227
  • SK Life Science, Inc.$215
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,676100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,676 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$29,424
Medicare patients
112
Services billed
855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin27$29,568
EliquisApixaban27$27,311
OzempicSemaglutide19$18,185
MounjaroTirzepatide17$15,532
FarxigaDapagliflozin Propanediol19$14,014
Levothyroxine Sodium157$1,917
Gabapentin128$1,643
Celecoxib22$1,499
Albuterol Sulfate HfaAlbuterol Sulfate56$1,111
Atorvastatin Calcium139$1,057
Duloxetine Hcl47$1,028
Omeprazole80$904
Trazodone Hcl23$890
SynthroidLevothyroxine Sodium14$818
Metoprolol Succinate51$752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$36$29,56827 claims
PfizerEliquis$73$27,31127 claims
Novo NordiskOzempic$99$18,18519 claims
Lilly USA, LLCMounjaro$306$15,53217 claims
AstraZenecaFarxiga$68$14,01419 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$1,917157 claims
AbbVieSynthroid$867$81814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Germantown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →